胰腺癌新辅助治疗临床研究进展

Clinical researches and developments of neoadjuvant therapy in pancreatic cancer

胰腺癌恶性程度高、预后差,手术仍然是根治胰腺癌的唯一手段,然而大部分患者在诊断时即是中晚期,丧失了根治性手术的机会。随着新辅助治疗的推广应用,部分原本无法手术的患者降期后重新获得手术机会,生存时间显著延长。目前新辅助治疗药物组合、放化疗手段搭配以及手术时机选择都是研究热点。与此同时,免疫治疗和靶向治疗在多种恶性肿瘤中取得了较大进展,这也使得胰腺癌患者看到了新的希望。胰腺癌系统科学的治疗流程需要更多高等级循证医学数据指导,本文将就目前胰腺癌新辅助治疗临床研究进展和热点问题做一概述。

Pancreatic cancer is a kind of fatal diseases with extremely poor prognosis and radical resection is the only way to treat the disease.However,the majority of patients is in advanced stage and loses the chance of surgery when diagnosed.With the application of neoadjuvant therapy,the outcome of pancreatic cancer patients is improved significantly because some patients with advanced disease regain the opportunity of surgery after treatment.Recently,the researches involving in novel regimens,the combination of chemotherapy and radiotherapy,the timing of surgery are hot issues.Accumulative promising results of immunotherapy and targeted therapy are reported in some malignancies,it offers new hope for pancreatic cancer patients.More high-level evidences are strongly required to improve the treatment of pancreatic cancer.Therefore,we reviewed on clinical researches and developments in neoadjuvant therapy for pancreatic cancer.